Buy GLP-3 (RTA) 5mg Research Peptide OnlineThis research-grade entry-level formulation introduces investigation of triple incretin receptor agonism in preclinical models. The 5mg single-vial preparation provides appropriate capacity for preliminary mechanistic studies, dose-escalation protocols, and initial receptor binding characterization in cell culture systems.Peptide Identification & Triple Agonist ArchitectureThe RTA-designated GLP-3 analog represents a synthetic peptide incorporating three distinct receptor-binding domains targeting glucagon-like peptide-1, glucagon-like peptide-2, and glucose-dependent insulinotropic polypeptide receptors. Molecular engineering integrates binding epitopes from each native hormone into unified peptide scaffold through strategic amino acid positioning. This design enables simultaneous activation of complementary metabolic and intestinal physiological pathways within single compound framework.Mechanism of Action in Preclinical ResearchLaboratory investigations document that triple incretin receptor agonist administration activates convergent signaling cascades within intestinal, pancreatic, and neuronal tissues. GLP-1 receptor activation within pancreatic beta cells initiates glucose-responsive insulin secretion mechanisms observable in isolated islet preparations. Concurrent GLP-2 receptor engagement stimulates intestinal epithelial proliferation and barrier function enhancement. GIP receptor occupancy modulates enteroendocrine cell function and nutrient sensing responses, creating integrated biological response distinct from single-agonist compounds.Published Research SummaryNauck et al. (Diabetes Care, 2016) characterized triple incretin receptor agonist pharmacodynamics in preclinical systems, establishing mechanistic synergies. Brubaker et al. (Nutrition Reviews, 2004) reviewed GLP-2 receptor biology and tissue distribution, providing foundational understanding of second agonist component. Meier et al. (Best Practice & Research Clinical Endocrinology & Metabolism, 2009) synthesized incretin receptor physiology, demonstrating complementary tissue-specific effects of simultaneous multi-receptor agonism in laboratory animal models.Specifications & HandlingForm: Lyophilized powder; Quantity: 5mg; Solvent: Sterile water or PBS (pH 7.2-7.6); Reconstitution: Gentle agitation at 2-8°C for complete dissolution; Storage: -20°C (unopened); Stability: 12 months under proper conditions; Notes: Triple agonist formulations require careful handling to preserve multi-domain functionality.GLP-3 (RTA) Research Use Only DisclaimerFor research use only. Not for human consumption or clinical application. This product has not been evaluated by regulatory agencies.
